{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:05:26Z","timestamp":1778695526462,"version":"3.51.4"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304250"],"award-info":[{"award-number":["82304250"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273734"],"award-info":[{"award-number":["82273734"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003551"],"award-info":[{"award-number":["82003551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although programmed death (PD)-1 inhibitors inhibitors have been clinically approved for the treatment of lung adenocarcinoma (LUAD), only a few patients benefit from anti-PD-1 therapy. We developed a semi-supervised biological sparse neural network (sBiosNet) based on transfer learning to fully utilize labeled and unlabeled patient data. The pathways from the Reactome database were used to sparse the sBiosNet and extract associated biological features by integrating patients\u2019 genomic mutations and copy number variation data. We assessed the performance of the sBiosNet against random forest and support vector machine using four cohorts and provided clear interpretations using the DeepLIFT algorithm. The sBiosNet achieved the best prediction with an area under the receiver operating characteristic curve (AUROC) of 0.888 and an area under the precision recall curve (AUPR) of 0.919 for responders versus non-responders on the validation cohort, and AUROC of 0.853 and AUPR of 0.894 on an independent external cohort. The ablation experiments demonstrated that biological sparsification and multi-omics data integration, transfer learning and semi-supervised learning all contributed to improving the sBiosNet\u2019s performance. We further confirmed that genes (such as TP53, FGF3, FGFR4, and EGFR) affected LUAD patients\u2019 response to PD-1 inhibitors by regulating pathways. Meanwhile, the Low-risk LUAD patients identified by the sBiosNet obtained significant longer overall survival and progression-free survival with anti-PD-1 therapy. In conclusion, the sBiosNet accurately predicts the response and survival of patients on anti-PD-1 therapy to reduce unnecessary treatment in non-responders.<\/jats:p>","DOI":"10.1093\/bib\/bbaf479","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:46:50Z","timestamp":1756381610000},"source":"Crossref","is-referenced-by-count":3,"title":["Predicting response and survival of lung adenocarcinoma under anti-programmed death-1 therapy using biological deep learning"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5086-3777","authenticated-orcid":false,"given":"Yuanyuan","family":"Wang","sequence":"first","affiliation":[{"name":"The College of Public Health, Shanghai University of Medicine & Health Sciences , 279 Zhouzhu Road, Pudong New Area, Shanghai 201318 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Xie","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Women\u2019s Hospital School of Medicine Zhejiang University , No. 1 Xueshi Rd, Hangzhou, Zhejiang 310006 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaru","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0583-0236","authenticated-orcid":false,"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2960-3169","authenticated-orcid":false,"given":"Kang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Public Health College, Harbin Medical University , No. 157, Baojian Road, Nangang District, Harbin City, Heilongjiang Province, 150081 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2025091922425364400_ref1","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s40265-016-0618-8","article-title":"Atezolizumab: First global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"2025091922425364400_ref2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2025091922425364400_ref3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s43018-023-00562-7","article-title":"EZH2i unlocks PDAC immune surveillance","volume":"4","author":"Damhofer","year":"2023","journal-title":"Nat Cancer"},{"key":"2025091922425364400_ref4","doi-asserted-by":"crossref","first-page":"e18761429310703","DOI":"10.2174\/0118761429310703240823045808","article-title":"Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation, Curr","volume":"17","author":"Sensi","year":"2024","journal-title":"Mol Pharmacol"},{"key":"2025091922425364400_ref5","doi-asserted-by":"crossref","first-page":"e140923221042","DOI":"10.2174\/1874467217666230914090621","article-title":"Targeting mutant-p53 for cancer treatment: Are we there yet?","volume":"17","author":"Lim","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"2025091922425364400_ref6","first-page":"e060923220758","article-title":"At the crossroads of TNF \u03b1 signaling and cancer","volume":"17","author":"Manohar","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"2025091922425364400_ref7","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1002\/imt2.130","article-title":"HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus-associated cancers","volume":"2","author":"Liu","year":"2023","journal-title":"Imeta"},{"key":"2025091922425364400_ref8","doi-asserted-by":"crossref","first-page":"2452277","DOI":"10.1080\/19490976.2025.2452277","article-title":"From chaos to order: Optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy","volume":"17","author":"Lin","year":"2025","journal-title":"Gut Microbes"},{"key":"2025091922425364400_ref9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-024-01972-6","article-title":"CTLs heterogeneity and plasticity: Implications for cancer immunotherapy","volume":"23","author":"Peng","year":"2024","journal-title":"Mol Cancer"},{"key":"2025091922425364400_ref10","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti\u2013PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025091922425364400_ref11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2025091922425364400_ref12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.resinv.2022.10.003","article-title":"Prognostic role of modified Glasgow prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies","volume":"61","author":"Tanaka","year":"2023","journal-title":"Respir Investig"},{"key":"2025091922425364400_ref13","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2025091922425364400_ref14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025091922425364400_ref15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"2025091922425364400_ref16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"2025091922425364400_ref17","doi-asserted-by":"crossref","DOI":"10.21037\/atm-22-1317","article-title":"The value of WNT5A as prognostic and immunological biomarker in pan-cancer","volume":"10","author":"Feng","year":"2022","journal-title":"Ann Transl Med"},{"key":"2025091922425364400_ref18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2025091922425364400_ref19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2025091922425364400_ref20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000381","article-title":"Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: A multicohort study","volume":"8","author":"Bai","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025091922425364400_ref21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"2025091922425364400_ref22","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB)\u2265 10: A decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"},{"key":"2025091922425364400_ref23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: Is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025091922425364400_ref24","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/ng.3677","article-title":"Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy","volume":"48","author":"Riaz","year":"2016","journal-title":"Nat Genet"},{"key":"2025091922425364400_ref25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","article-title":"Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2025091922425364400_ref26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"2025091922425364400_ref27","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025091922425364400_ref28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CJI.0000000000000475","article-title":"Biologically interpretable deep learning to predict response to immunotherapy in advanced melanoma using mutations and copy number variations","volume":"46","author":"Zhang","year":"2023","journal-title":"J Immunother"},{"key":"2025091922425364400_ref29","doi-asserted-by":"publisher","first-page":"D687","DOI":"10.1093\/nar\/gkab1028","article-title":"The reactome pathway knowledgebase 2022","volume":"50","author":"Gillespie","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2025091922425364400_ref30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"2025091922425364400_ref31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025091922425364400_ref32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti\u2013programmed cell death (PD)-1 and anti\u2013programmed death-ligand 1 (PD-L1) blockade in patients with non\u2013small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025091922425364400_ref33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"2025091922425364400_ref34","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","article-title":"Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors","volume":"50","author":"Miao","year":"2018","journal-title":"Nat Genet"},{"key":"2025091922425364400_ref35","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/1878-0261.12891","article-title":"Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"15","author":"Frigola","year":"2021","journal-title":"Mol Oncol"},{"key":"2025091922425364400_ref36","doi-asserted-by":"publisher","first-page":"E2423","DOI":"10.1002\/humu.22771","article-title":"Oncotator: Cancer variant annotation tool","volume":"36","author":"Ramos","year":"2015","journal-title":"Hum Mutat"},{"key":"2025091922425364400_ref37","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1039\/C3AY41907J","article-title":"Principal component analysis","volume":"6","author":"Bro","year":"2014","journal-title":"Anal Methods"},{"key":"2025091922425364400_ref38","article-title":"Visualizing data using t-SNE","volume":"9","author":"Van der Maaten","year":"2008","journal-title":"J Mach Learn Res"},{"key":"2025091922425364400_ref39","doi-asserted-by":"crossref","DOI":"10.21105\/joss.00861","article-title":"Umap: Uniform manifold approximation and projection for dimension reduction","volume":"3","author":"McInnes","year":"2018","journal-title":"J Open Source Softw"},{"key":"2025091922425364400_ref40","doi-asserted-by":"crossref","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025091922425364400_ref41","article-title":"Distilling the knowledge in a neural network","volume-title":"Computer Science","author":"Hinton"},{"key":"2025091922425364400_ref42","volume-title":"International Conference on Machine Learning","author":"Guo","year":"2017"},{"key":"2025091922425364400_ref43","volume-title":"Workshop on Challenges in Representation Learning, Atlanta, ICML","author":"Lee","year":"2013"},{"key":"2025091922425364400_ref44","article-title":"Mixup: Beyond empirical risk minimization","author":"Zhang"},{"key":"2025091922425364400_ref45","volume-title":"International Conference on Machine Learning","author":"Shrikumar","year":"2017"},{"key":"2025091922425364400_ref46","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"2025091922425364400_ref47","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1158\/1078-0432.CCR-18-3041","article-title":"A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer","volume":"25","author":"Trefny","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025091922425364400_ref48","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"2025091922425364400_ref49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"key":"2025091922425364400_ref50","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025091922425364400_ref51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12859-023-05268-2","article-title":"Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis","volume":"24","author":"Li","year":"2023","journal-title":"BMC Bioinformatics"},{"key":"2025091922425364400_ref52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: From mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2025091922425364400_ref53","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-19-3976","article-title":"Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025091922425364400_ref54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-021-02031-3","article-title":"Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy","volume":"19","author":"Long","year":"2021","journal-title":"BMC Med"},{"key":"2025091922425364400_ref55","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"2025091922425364400_ref56","doi-asserted-by":"crossref","first-page":"813732","DOI":"10.3389\/fimmu.2022.813732","article-title":"EGFR mutation and 11q13 amplification are potential predictive biomarkers for immunotherapy in head and neck squamous cell carcinoma","volume":"13","author":"Dou","year":"2022","journal-title":"Front Immunol"},{"key":"2025091922425364400_ref57","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025091922425364400_ref58","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti\u2013programmed cell Death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"key":"2025091922425364400_ref59","doi-asserted-by":"crossref","first-page":"991091","DOI":"10.3389\/fimmu.2022.991091","article-title":"PTPRD\/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types","volume":"13","author":"Shang","year":"2022","journal-title":"Front Immunol"},{"key":"2025091922425364400_ref60","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.3934\/mbe.2022251","article-title":"An integrative prognostic and immune analysis of PTPRD in cancer","volume":"19","author":"Ou","year":"2022","journal-title":"Math Biosci Eng"},{"key":"2025091922425364400_ref61","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025091922425364400_ref62","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1101\/gr.180612.114","article-title":"Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution","volume":"25","author":"Kim","year":"2015","journal-title":"Genome Res"},{"key":"2025091922425364400_ref63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13073-016-0333-9","article-title":"The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine","volume":"8","author":"Garofalo","year":"2016","journal-title":"Genome Med"},{"key":"2025091922425364400_ref64","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/annonc\/mdz205","article-title":"Optimizing panel-based tumor mutational burden (TMB) measurement","volume":"30","author":"Budczies","year":"2019","journal-title":"Ann Oncol"},{"key":"2025091922425364400_ref65","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2020.01.019","article-title":"Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement","volume":"142","author":"Budczies","year":"2020","journal-title":"Lung Cancer"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/26\/5\/bbaf479\/64325588\/bbaf479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/26\/5\/bbaf479\/64325588\/bbaf479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T02:43:08Z","timestamp":1758336188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbaf479\/8258647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaf479","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,31]]},"article-number":"bbaf479"}}